MedPath

Feasibility of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention Deficit Disorder (ADD).

Phase 1
Conditions
Adult Attention Deficit Disorder
Interventions
Device: Transcranial Direct Current Stimulation
Registration Number
NCT02206516
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Brief Summary

This study aims at combining imaging techniques and clinical evaluations to assess clinical change as well as brain changes that occur as a result of brain stimulation in adult attention deficit disorder.

Detailed Description

This study will use clinical measures and cognitive tasks covering 3 different functional domains during functional magnetic resonance imaging (fMRI), ElectroEncephaloGram (EEG) and Ultrasound tagged near infrared spectroscopy (UT-NIRS), to assess functional brain changes as a result of a treatment protocol with Transcaranial direct current stimulation (tDCS) in adults suffering from attention deficit disorder (ADD).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  1. Patients between the ages of 18-65(male and female)
  2. Diagnosed as suffering from Attention-Deficit Hyperactivity Disorder according to the DSM IV
  3. Patients taking medication for ADHD will give their consent to stop those medication 48 before entering the study and throughout the daily treatments.
  4. Gave informed consent for participation in the study
  5. If referred by the treating psychiatrist, he or she approves of the subjects participation in the study
Exclusion Criteria
  1. Suffering from other diagnosis on axis 1
  2. History of drug or alcohol abuse during the last year
  3. Inability to achieve satisfying level of communication with the subject

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
patientsTranscranial Direct Current StimulationStimulation using tDCS will be administered daily, 5 days a week for 4 weeks. each session will last 22 minutes during which the anode electrode will be positioned over the right Inferior Frontal Gyrus (IFG) and the Katode electrode over the right Orbito Frontal Gyrus (OFG).
Primary Outcome Measures
NameTimeMethod
Efficacy will be examined by the change in the CAARS questionnaire from the baseline visit to the determination visit in the treatment group compared to the control group.6 weeks
Secondary Outcome Measures
NameTimeMethod
changes in functional activity after 4 weeks of tDCS treatment during response inhibition6 weeks

ROI analysis of right Inferior frontal cortex will be measured during response inhibition in the Go/Nogo task at the end of the 4 weeks of treatment and will be compared to baseline measures.

Trial Locations

Locations (1)

TASMC

🇮🇱

Tel Aviv, Israel

© Copyright 2025. All Rights Reserved by MedPath